Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib
Yun‐Feng Wu, Jing‐Suo Wang, Chuan‐Ao Zhang, Fan Zhang, Zhi‐Yu Zhang. Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib. // Kaohsiung Journal of Medical Sciences. – 2026. – DOI: 10.1002/kjm2.70307. – URL: https://onlinelibrary.wiley.com/doi/10.1002/kjm2.70307?af=R
Yun‐Feng Wu, Jing‐Suo Wang, Chuan‐Ao Zhang, Fan Zhang, & Zhi‐Yu Zhang (2026). Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib. Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70307
Yun‐Feng Wu, et al. “Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib.” Kaohsiung Journal of Medical Sciences, 2026. doi:10.1002/kjm2.70307.
@article{Wu2026,
title = {Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib},
author = {Wu, Yun‐Feng and Wang, Jing‐Suo and Zhang, Chuan‐Ao and Zhang, Fan and Zhang, Zhi‐Yu},
journal = {Kaohsiung Journal of Medical Sciences},
year = {2026},
doi = {10.1002/kjm2.70307},
url = {https://onlinelibrary.wiley.com/doi/10.1002/kjm2.70307?af=R}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...